Intranasal administration of active agents to the central nervous system
View Patent ↗Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.
1. A method of delivering a therapeutic composition to the central nervous system of a mammal, comprising intranasally administering a therapeutically effective amount of an aqueous composition comprising a therapeutic polypeptide and a compound selected from the group consisting of: 1-O-n-dodecyl-beta-D-maltopyranoside, 1-O-n-decyl-beta-D-maltopyranoside, 1-O-n-tetradecyl-beta-D-maltopyranoside, and beta-D-fructopyranosyl-alpha-glucopyranoside monododecanoate, wherein the compound is present in the aqueous composition at a concentration between 0.125 g to 1 g per 100 ml of the aqueous composition.
2. The method of claim 1 , wherein the polypeptide is absorbed across nasal epithelium.
3. The method of claim 2 , wherein the polypeptide is selected from insulin, leutenizing hormone releasing (LHRH) and agonists of LHRH; nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3, neurotrophin-4/5; acidic fibroblast growth factor and basic fibroblast growth factor; ciliary neurotrophic factor, leukemia inhibitory factor, and cardiotrophin-1; transforming growth factor-beta-1-3 (TGF-betas), bone morphogenetic proteins (BMPs), growth differentiation factors 5 to 15, glial cell line-derived neurotrophic factor (GDNF), neurturin, artemin, activins and persephin; epidermal growth factor, transforming growth factor-alpha and neuregulins; insulin-like growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2); Pituitary adenylate cyclase-activating polypeptide-27 (PACAP-27), PACAP-38, glucagons, Glucagon-like peptide-1 (GLP-1), GLP-2, growth hormone releasing factor, vasoactive intestinal peptide (VIP), peptide histidine methionine, secreting and glucose-dependent insulinotropic polypeptide; activity-dependent neurotrophic factor and platelet-derived growth factors (PDGFs).
4. The method of claim 2 , wherein the polypeptide is exendin-4.
5. The method of claim 1 , wherein the composition has a pH of between about 4 and 8.
6. The method of claim 1 , wherein the compound is present in the aqueous composition at a concentration of 0.5 g per 100 ml of aqueous composition.